Executive Summary—Key Findings

Executive Summary—Key Findings (continued)

Executive Summary—Key Findings (continued)

Antibacterial Drugs Market—Game-changing Strategies

Key Merger, Acquisition, and Partnership Assessment

Key Merger, Acquisition, and Partnership Assessment (continued)

Key Merger, Acquisition, and Partnership Assessment (continued)

Key Merger, Acquisition, and Partnership Assessment (continued)

Key Merger, Acquisition, and Partnership Assessment (continued)

Methodology and Scope

Introduction

Introduction (continued)

Market Overview—Segmentation

Antibacterial Drugs—Approved and Novel Product Classes Synopsis

Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)

Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)

Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)

Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)

Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)

Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)

Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)

Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)

Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)

Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)

Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)

Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)

Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)

Dosing Regimen of Commonly Prescribed Antigens

Dosing Regimen of Commonly Prescribed Antigens (continued)

Dosing Regimen of Commonly Prescribed Antigens (continued)

Dosing Regimen of Commonly Prescribed Antigens (continued)

Dosing Regimen of Commonly Prescribed Antigens (continued)

Dosing Regimen of Commonly Prescribed Antigens (continued)

Dosing Regimen of Commonly Prescribed Antigens (continued)

Dosing Regimen of Commonly Prescribed Antigens (continued)

Dosing Regimen of Commonly Prescribed Antigens (continued)

Dosing Regimen of Commonly Prescribed Antigens (continued)

Dosing Regimen of Commonly Prescribed Antigens (continued)

Dosing Regimen of Commonly Prescribed Antigens (continued)

Dosing Regimen of Commonly Prescribed Antigens (continued)

Dosing Regimen of Commonly Prescribed Antigens (continued)

Antibacterial Drugs—Competitive Landscape of Products in Development

Antibacterial Drugs—Pipeline Analysis

Antibacterial Drugs—Pipeline Synopsis

Antibacterial Drugs—Pipeline Synopsis (continued)

Antibacterial Drugs—Pipeline Synopsis (continued)

Antibacterial Drugs—Pipeline Synopsis (continued)

Antibacterial Drugs—Pipeline Synopsis (continued)

Antibacterial Drugs—Pipeline Synopsis (continued)

Antibacterial Drugs—Pipeline Synopsis (continued)

Antibacterial Drugs—Pipeline Synopsis (continued)

Antibacterial Drugs—Pipeline Synopsis (continued)

Antibacterial Drugs—Pipeline Synopsis (continued)

Antibacterial Drugs—Pipeline Synopsis (continued)

Antibacterial Drugs Market—Major Ongoing/Recently Completed Clinical Trials

Antibacterial Drugs Market—Major Ongoing/Recently Completed Clinical Trials (continued)

Antibacterial Drugs Market—Major Ongoing/Recently Completed Clinical Trials (continued)

Tedizolid Phosphate—Cubist Pharmaceuticals

Dalbavancin (Dalvance™)—Durata Therapeutics

Ceftolozane + Tazobactam—Cubist Pharmaceuticals

Oritavancin (Orbactiv™)—The Medicines Company

Ceftazidime + Avibactam (CAZ-AVI)—AstraZeneca

Cadazolid—Actelion Pharmaceuticals

Carbavance—Rempex Pharmaceuticals (The Medicines Company)

Delafloxacin—Melinta Therapeutics

Eravacycline—Tetraphase Pharmaceuticals

Plazomicin—Achaogen

Solithromycin—Cempra Pharmaceuticals

Surotomycin—Cubist Pharmaceuticals

Common Mechanisms of Antibiotic Resistance

Key Challenges to Antibiotic Research & Development

Hard-to-treat Pathogens/Superbugs That Pose a Serious Threat to Drug Makers

New Antibiotics in the Pipeline That Help Overcome Drug Resistance

New Antibiotics in the Pipeline That Help Overcome Drug Resistance (continued)

New Antibiotics in the Pipeline That Help Overcome Drug Resistance (continued)

New Antibiotics in the Pipeline That Help Overcome Drug Resistance (continued)

New Antibiotics in the Pipeline That Help Overcome Drug Resistance (continued)

Antibacterial Drug Classes—FDA Approval Timeline

Antibacterial Drug Classes—FDA Approval Timeline (continued)

Antibacterial Drugs—FDA Approval Timeline

Antibacterial Drugs Market—Timeline of Key Events

Antibacterial Drugs Market—Timeline of Key Events (continued)

Regulatory Policies to Stimulate Antibiotics R&D

Generating Antibiotics Incentives Now (GAIN) Act

Implementation of the (GAIN) Act

Antibiotic Development to Advance Patient Treatment Act (ADAPT): H.R. 3742

IDSA’s 10 x ‘20 Initiative

Additional Economic Incentives—Tax Credits

Additional Economic Incentives—Federal Research Funding

Additional Economic Incentives—Federal Research Funding (continued)

Additional Economic Incentives—Federal Research Funding (continued)

PPPs—The European Effort

PPPs—The European Effort (continued)

PPPs—BARDA

PPPs—BARDA (continued)

Key Companies to Watch

Key Companies to Watch (continued)

Conclusions and Recommendations

Legal Disclaimer

List of Abbreviations

The Frost & Sullivan Story

Value Proposition

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy